Brain Advance Access originally published online on November 25, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 127, No. 2, 363-370, 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh046
Why is parkinsonism not a feature of human methamphetamine users?
1 Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, 2 Division of Neuropathology, London Health Science Centre, University of Western Ontario, London, Ontario, Canada, 3 Division of Forensic Toxicology, Office of the Armed Forces Medical Examiner, Division of Forensic Toxicology, Armed Forces Institute of Pathology, Rockville, MD, 4 Santa Clara County Medical Examiner-Coroner, San Jose, CA, 5 Arkansas State Crime Laboratory, 3 Natural Resources Drive, Little Rock, AR, 6 Spokane County Medical Examiner’s Office, Spokane and 7 Clark County Office of the Medical Examiner, Vancouver, WA, USA
Correspondence to: Stephen J. Kish, PhD, Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada E-mail: stephen_kish{at}camh.net
For more than 50 years, methamphetamine has been a widely used stimulant drug taken to maintain wakefulness and performance and, in high doses, to cause intense euphoria. Animal studies show that methamphetamine can cause short-term and even persistent depletion of brain levels of the neurotransmitter dopamine. However, the clinical features of Parkinson’s disease, a dopamine deficiency disorder of the brain, do not appear to be characteristic of human methamphetamine users. We compared dopamine levels in autopsied brain tissue of chronic methamphetamine users with those in patients with Parkinson’s disease and in a control group. Mean dopamine levels in the methamphetamine users were reduced more in the caudate (–61%) than in the putamen (–50%), a pattern opposite to that of Parkinson’s disease. Some methamphetamine users had severely decreased dopamine levels, within the parkinsonian range, in the caudate (up to 97% dopamine loss) but not in the putamen. As the putamen and caudate subserve aspects of motor and cognitive function, respectively, our data suggest that methamphetamine users are not parkinsonian because dopamine levels are not sufficiently decreased in the motor component of the striatum. However, the near-total reduction in the caudate could explain reports of cognitive disturbances, sometimes disabling, in some drug users, and suggests that treatment with dopamine substitution medication (e.g. levodopa) during drug rehabilitation might be helpful.
Key Words: Parkinson’s disease; caudate; putamen; methamphetamine; cognition
Abbreviations: MA = methamphetamine
Received July 8, 2003. Revised September 23, 2003. Accepted September 26, 2003.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Boileau, P. Rusjan, S. Houle, D. Wilkins, J. Tong, P. Selby, M. Guttman, J. A. Saint-Cyr, A. A. Wilson, and S. J. Kish Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker? J. Neurosci., September 24, 2008; 28(39): 9850 - 9856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Kish PhD Pharmacologic mechanisms of crystal meth Can. Med. Assoc. J., June 17, 2008; 178(13): 1679 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Fitzmaurice, J. Tong, M. Yazdanpanah, P. P. Liu, K. S. Kalasinsky, and S. J. Kish Levels of 4-Hydroxynonenal and Malondialdehyde Are Increased in Brain of Human Chronic Users of Methamphetamine J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 703 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-J. Wang, L. Chang, N. D. Volkow, F. Telang, J. Logan, T. Ernst, and J. S. Fowler Decreased brain dopaminergic transporters in HIV-associated dementia patients Brain, November 1, 2004; 127(11): 2452 - 2458. [Abstract] [Full Text] [PDF]
|
|